Skip to main content
. 2022 Jan 26;10(2):265. doi: 10.3390/biomedicines10020265

Figure 18.

Figure 18

Figure 18

(A,B) Myocardial infarction (1 isoprenaline challenge) and re-infarction (2 isoprenaline subsequent challenges) in isoprenaline-rats (75 mg/kg sc (gray bars), 150 mg/kg sc (white bars)). Gross heart lesions presentation. A–ECHOCARDIOGRAPHY, PRETREATMENT; B–ECHOCARDIOGRAPHY, POST-TREATMENT. Isoprenaline-rats treated with the smaller dose, 75 mg/kg sc (gray bars, italic letters), received medication (BPC 157 (10 ng/kg (b), 10 µg/kg (B) i.p. or saline (5 mL/kg i.p. (C)). Isoprenaline-rats treated with the higher dose, 150 mg/kg sc (white bars, normal letters), received medication (BPC 157 (10 ng/kg (b), 10 µg/kg (B) i.p. or saline (5 mL/kg i.p. (C)). Therapy was given (i) 30 min before isoprenaline (PRETREATMENT, prophylactic regimen (EF LV (%), 24 h, infarction (a), 48 h reinfarction (b), LDV (mL) diastolic volume, 24 h, infarction (c), 48 h reinfarction (d), LVSV (mL), end-diastolic volume, 24 h, infarction (e), 48 h reinfarction (f)) or, alternatively, (ii) at 5 min after isoprenaline (75 mg/kg s.c. or 150 mg/kg s.c.), at day 1 and at day 2 (POST-TREATMENT, therapeutic regimen (EF LV (%), 24 h, infarction (a), 48 h reinfarction (b), LDV (mL) diastolic volume, 24 h, infarction (c), 48 h reinfarction (d), LVSV (mL), end-diastolic volume, 24 h, infarction (e), 48 h reinfarction (f)). Ten rats per each experimental group. * p < 0.05 vs. control, at least.